Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3350956 | 1.00 | PADI4 (0.38) | PADI4ESR1POLBHCAR2CYP1A2 | |
| SCHEMBL745342 | 0.83 | KDM4E (0.50) | PADI4POLBHCAR2CYP1A2CYP2C19 | |
| SCHEMBL745343 | 0.83 | KDM4E (0.50) | PADI4POLBHCAR2CYP1A2CYP2C19 | |
| SCHEMBL29985733 | 0.82 | PADI4 (0.38) | PADI4ESR1POLBHCAR2SMN1; SMN2 | |
| SCHEMBL4172750 | 0.80 | KMT2A (0.44) | PADI4POLBHCAR2CYP1A2CYP3A4 | |
| SCHEMBL4172746 | 0.80 | KMT2A (0.44) | PADI4POLBHCAR2CYP1A2CYP3A4 | |
| SCHEMBL1368515 | 0.80 | ESR1 (0.38) | PADI4ESR1CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL1368514 | 0.80 | ESR1 (0.38) | PADI4ESR1CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL7293453 | 0.79 | CA12 (0.51) | POLBCYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL7293458 | 0.79 | CA12 (0.51) | POLBCYP1A2CYP3A4CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| EP-2744802-B1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| EP-2744802-B1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2016-05-19 | — | — | US | disclosed |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2016-05-19 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
| EP-2744802-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | Piramal Imaging SA (CH) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013023795-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013023795-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | PADI4 2748/4885ESR1 3446/4885POLB 1098/4885 |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | PADI4 741/4885ESR1 2368/4885POLB 3349/4885 |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | PADI4 741/4885ESR1 2368/4885POLB 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.